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Abstract
Background: Hemolytic uremic syndrome is characterized by acute renal failure, thrombocytopenia, and Coombs-
negative hemolytic anemia. In C3 mesangial proliferative glomerulonephritis, an increase in mesangial cell
proliferation without thickening in the glomerular capillary wall can be seen under light microscopy, but the
definitive diagnosis is made with the immunohistologic demonstration of isolated C3 deposits in the mesangium.
C3 glomerulonephritis may be detected in childhood; however, in this case report we describe the first case of
isolated C3 glomerulonephritis together with atypical hemolytic uremic syndrome in an adult patient.
Case presentation: Here we present a case of a 27-year-old white man with anuria who was hospitalized after
being diagnosed as having hemolytic uremic syndrome accompanied by acute renal failure. Renal biopsy results
revealed C3 glomerulonephritis. There was a complete recovery of renal function after hemodialysis, and
prednisolone and plasma exchange treatment.
Conclusions: C3 glomerulopathy is distinct from atypical hemolytic uremic syndrome although both diseases are
due to abnormal control of the alternative complement pathway. In atypical hemolytic uremic syndrome activation
of complement occurs on glomerular or microvascular endothelium causing a thrombotic microangiopathy; in
most cases, no electron-dense deposits are seen on electron microscopy and glomerular C3 is not detected on
immunofluorescence.
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Background
Advances in our understanding of the role of comple-
ment in the pathogenesis of membranoproliferative
glomerulonephritis (MPGN) have led to proposed re-
classification into immunoglobulin-mediated disease
(driven by the classical complement pathway) and non-
immunoglobulin-mediated disease (driven by the alter-
native complement pathway). In particular, the observa-
tion that immunofluorescence for a subset of patients
with MPGN stained only for C3 without immunoglobu-
lin, coupled with the unfolding of genetic and acquired
defects in the alternative complement pathway now
termed C3 glomerulopathy [1].
This is clinically characterized by non-immune
hemolytic anemia, low platelet count, and organ dys-
function. The European Pediatric Research Group has
divided thrombotic microangiopathies into two groups
according to their etiology: thrombotic thrombocytope-
nic purpura (TTP) and hemolytic uremic syndrome
(HUS) [2]. HUS is classically divided into the more com-
mon Shiga-like toxin-producing Escherichia coli HUS,
which is caused by a prodromal diarrheal illness and
linked to Shiga toxin-producing bacteria, and atypical
HUS (aHUS), a result of a genetic defect in complement
regulation [3, 4]. TTP and HUS can be difficult to differ-
entiate due to similar clinical presentation including
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microangiopathic hemolytic anemia, thrombocytopenia,
renal involvement, neurologic involvement, and fever.
However, while neurologic manifestations are predomin-
ant in TTP, renal involvement is more prominent in
HUS.
Case presentation
A 27-year-old white man with an unremarkable medical
and family history presented to our emergency depart-
ment with nausea, vomiting, fever reaching 38.8°C, and
bloody-mucoid diarrhea 10 to 13 times a day for the past
2 days. In that period, Salmonella had been found in
some meat cultures in the city center of Sivas and an en-
demic diarrhea presenting with the same clinical mani-
festations had been defined. He stated that he had eaten
from the meat that had previously been shown to con-
tain Salmonella. His blood pressure was 120/70 mmHg
and his pulse rate was 78/minute, but other physical
examination findings were normal. His baseline bio-
chemical analysis was unremarkable except for
leukocytosis of 21.6×103/mm3. Stool microscopy dem-
onstrated 7 to 8 red blood cells per high-power field and
1 to 2 white blood cells in some fields. No growth was
detected in his blood or stool cultures. He was hospital-
ized in the infectious diseases clinic for gastroenteritis,
and he was started on ciprofloxacin 500 mg treatment
twice daily.
One week after hospitalization, his laboratory results
were as follows: blood urea nitrogen 75 mg/dL, serum
creatinine 10.4 mg/dL, lactate dehydrogenase (LDH)
1539 U/L, total protein 4.5 g/dL (5.7 to 8.2), and albu-
min 2.8 g/dL (3.2 to 4.8). His urine analysis results were
normal. He was transferred to our nephrology depart-
ment because he was anuric, and the possibility of HUS
was under consideration. In that period, his blood pres-
sure was 130/80 mmHg, pulse rate was 84/minute, and
body temperature was 36°C; there were no pathologic
findings in his physical examination. There was no
growth in the specific stool culture performed for enter-
ohemorrhagic Escherichia coli. Two days later, his
hemoglobin (Hb) concentration dropped to 10 g/dL, dir-
ect Coombs test was negative, his reticulocyte ratio was
6 %, and there were schistocytes in his peripheral blood
smear. His serologic tests were negative for anti-nuclear
antibodies, cytoplasmic anti-neutrophil cytoplasmic anti-
bodies, hepatitis B surface antigen, antibodies to hepa-
titis B surface antigen, antibodies to hepatitis C virus
and human immunodeficiency virus, perinuclear anti-
neutrophil cytoplasmic antibody and anti-glomerular
basement membrane results; his C3 was 0.511 g/L (0.9
to 2.1) and C4 was 0.151 g/dL (0.1 to 0.4).
A urine analysis performed 2 weeks later when his
urine output began to increase, revealed +4 proteinuria
and normal microscopy, whereas micro-total protein in
24-hour urine was measured as 18 g/day. In addition,
valsartan 160 mg/day and prednisolone 1 mg/kg/day was
added to the treatment because his blood pressure in-
creased (maximum to 170/100 mmHg), and
hemodialysis and plasma exchange were commenced for
aHUS plus acute renal failure. His hemodialysis therapy
was discontinued after eight sessions because his cre-
atinine levels decreased and urine output increased.
Plasma exchange was performed for a total of 12 ses-
sions until his platelet count and LDH levels returned to
normal. He also received a red blood cell transfusion
(two units) for symptomatic anemia (Hb 7 g/dL,
hematocrit 22 %). The pathology report of the samples
obtained through renal biopsy was consistent with C3
glomerulonephritis; therefore, azathioprine 100 mg/day
was added to his treatment. A renal biopsy specimen
stained with hematoxylin and eosin revealed six glom-
eruli with increased mesangial cells and matrix, and
minimal focal interstitial lymphocytic inflammation.
There was no pathologic finding in the tubules and
blood vessels (Fig. 1). Direct immunofluorescence
staining of the tissue sections revealed a total of eight
glomeruli, which showed only mild to moderate
mesangial granular staining for C3; no immunofluor-
escent staining was detected with immunoglobulin A,
immunoglobulin G, immunoglobulin M, C1q, and fi-
brinogen. Congo red staining was negative. One
month later, his serum creatinine was found to be 1.1
mg/dL, LDH was 232 mg/dL, his platelet count was
190,000/mm3, Hb was 12.8 g/dL, albumin was 3.5, C3
was within the normal ranges, and the micro-total
protein in 24-hour urine was 1.3 g/day.
Discussion
HUS is characterized by microangiopathic hemolytic
anemia, thrombocytopenia, and renal dysfunction. In
HUS, reticulocyte numbers, indirect bilirubin, and LDH
levels increase as a result of intravascular hemolysis, and
haptoglobin levels decrease. Fragmented red blood cells
(schistocytes) and polychromasia are common in periph-
eral blood smears. C3 glomerulonephritis is recognized
by the presence of glomerulonephritis under light mi-
croscopy, immunofluorescent staining with C3, but not
with immunoglobulins, C4 or C1q, and the presence of
mesangial or subendothelial deposition, which can be
observed using electron microscopy [5–7]. C3 glomer-
ulonephritis results from deposition of C3 degradation
products and terminal complement components in
glomeruli that result from the activation of alternative
complement pathway due to the defects of complement-
regulating proteins. The immunohistologic diagnosis of
C3 glomerulonephritis is made based on the presence of
mesangial C3 deposition together with the absence of
immunoglobulin and other complement components
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[5]. Mesangial C3 deposition is seen in primary and sec-
ondary glomerulonephritis and in collagen diseases.
Clinically isolated hematuria appears in various forms,
ranging from normal renal function to end-stage renal
insufficiency. On pathological examination, it progresses
with mild glomerular abnormalities to various degrees of
mesangial cell proliferation and may be accompanied by
glomerulosclerosis. The clinical and laboratory findings
of our patient were not suggestive of autoimmune dis-
eases, such as systemic lupus erythematosus, or malig-
nant diseases. The presence of hypertension, heavy
proteinuria, renal dysfunction, severe mesangial prolifer-
ation, sclerotic glomeruli, interstitial fibrosis, tubular at-
rophy, and resistance to steroid therapy are indicators of
poor prognosis in C3 glomerulonephritis. Our patient
had renal dysfunction, hypertension, and heavy protein-
uria as indicators of poor prognosis. Glomerulonephritis
has been anecdotally reported in association with HUS.
Different types of glomerulopathies (membranous
glomerulonephritis, focal segmental glomerulosclerosis,
MPGN, immunoglobulin A nephropathy, C1q nephropa-
thy, and C3 glomerulonephritis) can be complicated by
HUS. Boyer et al. [8] reported two cases of HUS associ-
ated with complement factor H (CFH) deficiency in na-
tive kidneys, and glomerulonephritis with isolated C3
deposits after renal transplantation [9–13]. Genetic or
acquired C3 nephritic factor (C3NeF) abnormalities of
complement-regulating proteins are rarely associated
with C3 deposition. CFH plays a regulatory role in the
alternative complement pathway and its dysfunction
may lead to many renal diseases, such as HUS and C3
glomerulonephritis. Factor H, factor I, membrane cofac-
tor protein (MCP), and C3NeF were studied in a study
conducted on patients with isolated C3 deposition with-
out HUS. The patients were divided into two groups: the
first group consisted of patients with MPGN type 1 and
C3 deposition (n=13), and the second group comprised
patients with C3 glomerulonephritis with non-MPGN
C3 deposition (n=6). In group 1, C3NeF mutation was
detected in five patients and was indefinite in one, CFH
mutation was detected in one patient, and MCP muta-
tion was detected in one patient. In group 2, C3NeF mu-
tation was detected in two patients and was indefinite in
one, CFH mutation was detected in two patients, and
complement factor I mutation was detected in two pa-
tients. It was emphasized that patients with non-MPGN
type 1, that is, those with C3 glomerulonephritis, and
patients with HUS, share common genetic risk factors; a
relation was determined between the regulation of alter-
native pathway and genetic abnormalities in 70 % of the
patients [6].
Conclusions
In conclusion, glomerulonephritis diseases, particularly
those that coexist with isolated C3 glomerulonephritis
and aHUS, may be associated with CFH, complement
factor I, and MCP mutations. These mutations have been
demonstrated in both diseases. In addition, complement
mutations in other cases of glomerulonephritis have
been published as case reports. Improved understanding
of MPGN and, in particular, the activity of the alterna-
tive complement pathway in C3 glomerulopathies will
lead to improved outcomes with targeted therapy in
these patients.
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Fig. 1 Increased mesangial matrix and mesangial cells in the glomeruli. Focal lymphocytic inflammation was observed in the interstitium.
There was no pathological finding in the tubules and blood vessels. Picture on the left (a; HEx100); picture on the right (b; HEx200).
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